乳腺癌新辅助化疗前后 CD4+sTILs、CD8+sTILs、FOXP3+sTILs表达的变化及其临床意义OA
Dynamic changes in CD4+,CD8+,and FOXP3+tumor-infiltrating lympho-cytes during neoadjuvant chemotherapy for breast cancer and their clinical im-plications
目的 探究乳腺癌患者接受新辅助化疗后,CD4+肿瘤间质浸润淋巴细胞(sTILs)、CD8+sTILs及FOXP3+sTILs这3种sTILs亚型的表达改变,分析这些变化与临床治疗效果及临床病理特征之间的关联.方法 收集2015年至2019年遵义医科大学附属医院病理科80例接受新辅助化疗的乳腺癌患者临床资料.对新辅助化疗前的粗针穿刺活检标本蜡块组织,以及化疗后手术切除的配对标本蜡块组织,均采用免疫组化染色(IHC)技术,检测间质浸润免疫细胞(ICs)中CD4+sTILs、CD8+sTILs和FOXP3+sTILs的表达情况.结果 新辅助化疗实施后,CD4+sTILs与CD8+sTILs的浸润水平均有所上升,FOXP3+sTILs的浸润程度则呈现下降趋势,同时肿瘤细胞的ki-67增殖指数也有所降低.△sTILs(符号△代表表达变化量)与患者年龄(P=0.025)以及淋巴结转移(P=0.026)存在相关性.新辅助化疗后sTILs浸润增加组的△CD4+sTILs、△CD8+sTILs变化幅度显著高于sTILs浸润不变组和浸润减少组(P<0.001);而该组的△FOXP3+sTILs减少幅度明显低于sTILs浸润不变组与减少组(P<0.001).生存分析结果显示:△FOXP3+sTILs降低组的无病生存期(DFS)显著优于△FOXP3+sTILs升高组(P=0.024);而△sTILs、△CD4+sTILs、△CD8+sTILs各亚组间生存预后无明显差异.结论 新辅助化疗不仅能够促进肿瘤微环境中具有杀伤肿瘤能力的免疫细胞(CD4+sTILs、CD8+sTILs)向肿瘤组织浸润,还能抑制微环境中具有促肿瘤作用的淋巴细胞(FOXP3+sTILs)的浸润.客观评估新辅助化疗后肿瘤免疫相关指标的变化,对于临床预后判断及个体化治疗方案的制定具有积极意义.
Objective To investigate the dynamic changes in CD4+,CD8+,and FOXP3+tumor-infiltrating lymphocytes(TILs)following neoadjuvant chemotherapy for breast cancer and their associations with treatment response and clinicopathological features.Methods A total of 80 breast cancer cases treated with neoadjuvant chemotherapy in the Department of Pathology of the Affiliated Hospital of Zunyi Medical University from 2015 to 2019 were selected.Immunohistochemical staining(IHC)was performed on the pre-neoadjuvant chemotherapy core needle biopsy specimens and the matched post-chemotherapy surgical specimens to detect the expression of CD4+,CD8+and FOXP3+stromal tumor-infiltrating lymphocytes(sTILs)in the stromal infiltrating immune cells(ICs)of tumor tissues.Results After neoadjuvant chemotherapy,the infiltration levels of CD4+and CD8+sTILs increased,the infiltration degree of FOXP3+sTILs decreased,and the ki-67 proliferation index of tumor cells also decreased.△sTILs(the symbol △ represents the amount of expression change)was correlated with younger patient age(P=0.025)and no lymph node metastasis(P=0.026).The changes of △CD4+and△ CD8+sTILs in the group with increased sTILs infiltration after neoadjuvant chemotherapy were significantly higher than those in the groups with unchanged and decreased sTILs infiltration(P<0.001);while the reduc-tion range of △ FOXP3+sTILs in this group was significantly lower than that in the groups with unchanged and decreased sTILs infiltration(P<0.001).Survival analysis showed that the disease-free survival(DFS)of the△FOXP3+sTILs reduction group was significantly better than that of the △FOXP3+sTILs increase group(P=0.024).No significant differences or advantages were observed among groups with different sTILs changes(△sTILs),△CD4+sTILs groups,△CD8+sTILs groups.Conclusion Neoadjuvant chemotherapy promotes the infiltration of tumor-killing immune cells(CD4+and CD8+sTILs)while suppressing tumor-promoting FOXP3+sTILs within the tumor microenvironment.Objective assessment of these post-chemotherapy immune changes is valuable for clinical prognosis and guiding individualized treatment.
罗帅;田小雪;李瑶;王进京
遵义医科大学附属医院病理科,贵州遵义 563000遵义医科大学附属医院病理科,贵州遵义 563000遵义医科大学附属医院病理科,贵州遵义 563000遵义医科大学附属医院病理科,贵州遵义 563000
医药卫生
乳腺肿瘤新辅助化疗肿瘤间质浸润淋巴细胞亚型变化
breast neoplasmneoadjuvant chemotherapystromal tumour infiltrating lymphocytessubtypechange
《遵义医科大学学报》 2026 (9)
1020-1026,7
遵义市科技计划项目[NO:遵市科合HZ(2024)194]贵州省人口健康基金会项目[NO:2024GZYXKYJJXM0029].
评论